AMENDMENTS TO THE CLAIMS

1. (Original) A compound which is highly selective for CRFR1 without having any significant cross-reactivity for corticotropin-releasing-factor-receptor-2 (CRFR2) and/or corticotropin-releasing-factor-binding protein (CRFBP), said compound comprising or alternatively consisting of the amino acid sequence

Glx^{1}-Gly^{2}-Pro^{3}-Pro^{4}-Xaa^{5}-Ser^{6}-Xaa^{7}-Asp^{8}-Leu^{9}-Xaa^{10}-Leu^{11}-Glu^{12}-Leu^{13}-Leu^{14}-Arg^{15}-Glu^{16}-Val^{17}-Leu^{18}-Glu^{19}-Xaa^{20}-Xaa^{21}-Arg^{22}-Ala^{23}-Xaa^{24}-GIn^{25}-Leu^{26}-Ala^{27}-Gln^{28}-GIn^{29}-Ala^{30}-Ala^{11}-Asn^{32}-Asn^{33}-Arg^{34}-Leu^{35}-Leu^{36}-Leu^{37}-Asp^{38}-Thr^{39}-Ala^{40} (SEQID No: 1).

2. (Original) The compound of claim 1 wherein:

(a) Xaa^{5} is lie, Leu or any amino acid residue having similar physicochemical characteristics as lie; and/or

(b) Xaa^{7} isIle, Leu or an amino acid residue having similarphysicochemical characteristics as Ile; and/or

(c) Xaa^{10} is Ser, Thr or an amino acid residue having similar physicochemical characteristics as Serin; and/or

(d) Xaa^{20} is Met, Norleucine or any amino acid residue having similar physicochemical characteristics as Met; and/or

(e) Xaa^{21} is Glu, Asp or an amino acid residue having similarphysicochemical characteristics as Glu; and/or

(f) Xaa^{24} is Glu, Asp or an amino acid residue having similarphysicochemical characteristics as Glu.

3. (Original) The compound of claim 1 or 2 which is Glx^{1}-Gly^{2}-Pro^{3}-Pro^{4}-Ile^{5}-Ser^{6}-Ile^{7}-Asp^{8}-Leu^{9}-Ser^{10}-Leu^{11}-Glu^{12}-Leu^{13}-Leu^{14}-Arg^{15}-Glu^{16}-Val^{17}-Leu^{18}- Gluj ^{9}-Met^{20}-GIu^{21}-Arg^{22}-Ala^{23}-GIu^{24}-$G1n^{25}$-Leu^{26}-Ala^{27}-Gin^{28}-GIn^{29}-Ala^{30}-Ala^{31}-Asn^{32}-Asn^{33}-Arg^{34}-Leu^{35}-Leu^{36}-Leu^{37}-Asp^{38}-Thr^{39}-Aia^{40} (SEQ ID No: 2).

4. (Currently Amended) A nucleic acid molecule encoding the compound of ~~any one of claims 1 to 3~~ claim 1.

5. (Original) A vector comprising the nucleic acid molecule of claim 4.

6. (Currently Amended) The compound of ~~any one of claims 1 to 3~~ claim 1 which is labelled.

7. (Currently Amended) The compound of ~~any one of claims 1 to 3~~ claim 1 which is modified by:

(a) formation of pharmaceutical acceptable salts;

(b) formation ofpharmaceutically acceptable complexes; and/or

(c) synthesis ofpharmacologically active polymers.

8. (Currently Amended) A pharmaceutical composition comprising the compound of ~~any one of claims 1,2, 3,6 or 7~~ claim 1 and/or the nucleic acid ~~of claim 4~~ and/or the vector ~~of claim 5~~ and optionally a pharmaceutical acceptable carrier and/or diluent.

9. (Currently Amended) A diagnostic composition comprising the compound of ~~any one of claims 1,2, 3,6 or 7~~ claim 1.

10. (Currently Amended) A kit comprising the compound of ~~any one of claims 1,2, 3,6 or 7~~ claim 1 and/or the nucleic acid ~~of claim 4~~ and/or the vector ~~of claim 5~~ and optionally instructions to use.

11. (Currently Amended) Use of the compound of ~~any one of claims 1,2, 3,6 or 7~~ claim 1 and/or the nucleic acid ~~of claim 4~~ and/or the vector ~~of claim 5~~ for the preparation of a pharmaceutical composition for the treatment of depression.

12. (Original) The use of claim 11, wherein said depression is exogenic (like pharmacogenic), endogenic (like vital), psychogenic, agitated,anaclitic, arteriosclerotic, reactive and/or senile depression.

13. (Currently Amended) Use of the compound of ~~any one of claims 1,2, 3,6 or 7~~ claim 1 for the preparation of a diagnostic composition for the determination of pituitary corticotroph responsiveness.

14. (Original) The use of claim 13 for differentiating pituitary and ectopic production of ACTH in patients with ACTH-dependent Cushing's syndrome.